Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a better medication review keep older adults out of the hospital?

NCT ID NCT05899114

Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This trial tests whether a structured medication review and care coordination (TMPC) can reduce drug-related hospital readmissions in adults aged 70 and older who take five or more regular medications. Participants receive a detailed medication analysis, discussions among hospital and community doctors, and a patient interview. The study compares this approach to usual care to see if it lowers readmissions within 30 days and is cost-effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Transitional Multidisciplinary Pharmacotherapeutic Care (TMPC) - a structured medication review with care coordination
What this could lead to
If effective, this approach could reduce drug-related hospital readmissions and improve medication safety for older adults taking multiple medications.
What could go wrong
This is a single trial testing a complex care process, and results may vary across hospitals. The benefit may be modest or not generalizable to all older patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,241 people

The number who actually took part.

Started

Jun 2023

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

70 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 70 years or older * Polypharmacy, the use of 5 or more regular medications, defined as authorised medications with registration numbers, used for more than 30 days. Topical preparations are excluded from this definition. * Admitted to hospital through the ED (which comprises both the general emergency department and the cardiac emergency department) * Length of hospitalisation more than 24 hours * Completed medication verification * DRA prediction percentage of 23.0% or higher Exclusion Criteria: * No informed consent by patient or a legal representative * Participation in an interfering clinical trial * Elective hospital admission * Direct admission to the ICU (when medication verification as usual can't be executed, and therefore inclusion of patients as described in 10.2 is not possible) * A life expectancy of less than 3 months, which includes patients with palliative treatment at home, direct admission to palliative care or palliative care planned within 24 hours after index hospital admission. * Patient or legal representative not able to speak Dutch. * Follow-up of patient primarily by secondary caregivers. This refers to situations where the secondary caregiver is in the lead of the medication list of the patient instead of the GP or elderly care physician, for example in the following patient groups: * patients receiving intensive oncologic therapy * patients in an organ- or stem cell transplantation procedure * patients receiving intensive (chronic) psychiatric care, such as patients admitted to a medical psychiatric unit * patients on dialysis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Medication review are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Medication review Polypharmacy

Contacts and locations

Locations

  • Amphia ziekenhuis

    Breda, North Brabant, Netherlands

  • Amsterdam UMC - location VUMC

    Amsterdam, North Holland, Netherlands

  • Amsterdam UMC- location AMC

    Amsterdam, North Holland, Netherlands

  • Canisius Wilhelmina Ziekenhuis

    Nijmegen, Gelderland, Netherlands

  • Catharina Ziekenhuis

    Eindhoven, North Brabant, Netherlands

  • Deventer Ziekenhuis

    Deventer, Overijssel, Netherlands

  • Diakonessenhuis

    Utrecht, Utrecht, Netherlands

  • Erasmus Medisch Centrum Rotterdam

    Rotterdam, South Holland, Netherlands

  • Haga Ziekenhuis

    The Hague, South Holland, Netherlands

  • Leiden Universitair Medisch Centrum

    Leiden, South Holland, Netherlands

  • Meander Medisch Centrum Amersfoort

    Amersfoort, Utrecht, Netherlands

  • Radboudumc

    Nijmegen, Gelderland, Netherlands

  • Universitair Medisch Centrum Groningen

    Groningen, Provincie Groningen, Netherlands

  • Universitair Medisch Centrum Utrecht

    Utrecht, Utrecht, Netherlands

  • Zaans Medisch Centrum

    Zaandam, North Holland, Netherlands

  • Ziekenhuisgroep Twente

    Almelo, Overijssel, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.